<unk>  is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia)  and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).
Like other thiazolidinediones, the mechanism of action of<unk>  is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ.<unk>  is a selective ligand of PPARγ, and has no PPARα-binding action.
Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on<unk> .
Recent research has suggested that<unk>  may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele.  This is the subject of a clinical trial currently underway.
Rosiglitazone detailed information
Glimepiride detailed information
Metoprolol detailed information
Donepezil detailed information
Blood cholesterol LDL and non-HDL treatment goals
Diabetes dietary recommendations of american diabetes association
Esmolol detailed information
Diabetes dietary recommendations of american association of clinical endocrinologists